An analysis published on Seeking Alpha highlights the Schwab U.S. Dividend Equity ETF (SCHD) as a strong option for long-term investors due to its blend of value, quality, and low fees. The article recommends SCHD as a buy, noting its track record of dividend growth despite recent underperformance. It emphasizes the fund's unique selection process that differentiates it from broader market strategies.
The Schwab U.S. Dividend Equity ETF (SCHD), managed by Schwab, targets dividend-paying U.S. companies with a focus on fundamentals. According to a Seeking Alpha article published on February 24, 2026, SCHD provides long-term investors with a mix of value characteristics, quality holdings, and low expense ratios, making it an attractive choice in the ETF space. The analyst describes it as an 'excellent value fund' for those with a long horizon. The fund's portfolio construction relies on fundamentals-based criteria, resulting in limited overlap with the wider value investment category. This approach can produce returns that diverge significantly from broader benchmarks, as noted in the analysis. Over the past decade, SCHD's annual reconstitution process has driven double-digit annualized dividend growth while sustaining an above-average yield. Despite these strengths, the article acknowledges challenges, including three consecutive years of underperformance leading into 2026. Such periods are described as typical for differentiated strategies like SCHD's, which may experience bouts of lagging returns due to its methodology. However, the combination of quality and value factors is said to position the fund well for performance over extended periods. The Seeking Alpha piece, authored by an independent analyst, includes standard disclosures: the writer holds no positions in mentioned securities and expresses personal opinions without compensation beyond the platform. Seeking Alpha itself clarifies that the views do not represent the site's overall stance and that past performance does not guarantee future results. This analysis underscores SCHD's appeal for patient investors seeking dividend-focused exposure amid varying market conditions.
